

Catabolism of capped (3'-5')- and (2'-5')-adenylates in rat liver nuclei

Winfried Michels and Eckhard Schlimme

Laboratorium für Biologische Chemie im Fachgebiet, Organische Chemie der Universität (GH), Warburger Straße 100, D-4790 Paderborn, FRG

Received 17 October 1983

We describe studies concerning the ability of a nuclear dinucleoside triphosphatase to act as a decapping enzyme in RNA catabolism. The enzymatic release of GMP from the Gp₃A moiety was determined in the capped RNA model compounds Gp₃A3'pA, Gp₃A3'pA-isoprop and Gp₃A2'pA in isolated rat liver nuclei; i.e., in the environment in which the dinucleoside triphosphatase operates in vivo. The Gp₃A cap moiety is hydrolyzed in (3'-5') linked nucleotides only, whereas an extension of the Gp₃A in the 2'-direction prevents the nuclear triphosphatase to operate.

<i>5'-Capped (3'-5')-adenylate</i>	<i>5'-Capped (2'-5')-adenylate</i>	<i>Capped RNA fragment</i>
<i>Decapping activity</i>	<i>Nuclear dinucleoside triphosphatase</i>	<i>RNA catabolism</i>
	<i>Rat liver nucleus</i>	<i>RNA recycling</i>

1. INTRODUCTION

The 5'-terminal cap structures in eukaryotic messenger RNA (mRNA) [1-4] are known to impart stability to these molecules against 5'-3' exoribonucleolytic attack [5-11]. In the degradation pathway of cytoplasmic mRNA as well as nuclear heterogeneous RNA (hnRNA), on the other hand, there must exist enzymatic steps for hydrolyzing caps, capped RNA or RNA-fragments. Otherwise, such capped structures would accumulate and affect the biological functioning of the cell.

Such decapping activities were found for instance in different mammalian and vegetable tissues [10,12-15]. The enzymatic cleavage of the cap from either mRNA [10,12,16], capped mRNA-fragments bearing less than 3 [17] or 8 [7] nucleotides in the 3'-direction, respectively, or of cap structured dinucleotides [16,18,19] follows the mode of action of a dinucleoside triphosphatase. This is confirmed by the cleavage pattern as the enzymatic breakdown lead to the formation of m⁷GDP [10], m⁷GMP [12,16-19] and GMP [16-19] from naturally occurring capped

oligoribonucleotides as well as synthetic dinucleoside triphosphates.

In [18] it was reported that a dinucleoside triphosphatase (EC 3.6.1.x) of rat liver nuclei specifically recognizes and hydrolyzes Gp₃A which is the non-methylated parent compound of caps and present in nuclear RNA precursors since cap formation is an early event in hnRNA synthesis [20]. Furthermore, from studies with lymphocyte nuclei it is known that these cells process their hnRNA rather slowly, thereby accumulating capped but not yet methylated species [21]. This paper contains studies concerning the ability of the nuclear triphosphatase to hydrolyze the Gp₃A moiety in Gp₃A3'pA, Gp₃A3'pA-isoprop and Gp₃A2'pA (fig.1); i.e., when:

- Gp₃A bears an additional AMP-moiety adjacent to the cap in the 3'-direction;
- the terminal hydroxyl functions of the additional AMP-moiety are protected by an 2',3'-isopropylidene group;
- Gp₃A is extended by an additional AMP-moiety in the 2'-direction.

We have performed our decapping studies with




Fig.1. Capped (3'-5')- and (2'-5')-adenylates.

the aforementioned capped RNA model compounds in isolated nuclei; i.e., in the environment in which the dinucleoside triphosphatase operates *in vivo*. Some of our findings have been published in part as a poster contribution [22].

2. MATERIALS AND METHODS

[³H]Gp₃A3'pA and [³H]Gp₃A3'pA-isoprop as well as [³H]Gp₃A2'pA were prepared by the reaction of carbonyldiimidazole-activated pA3'pA, pA3'pA-2',3'-isopropylidene as well as pA2'pA, respectively with [³H]GDP which was purchased from New England Nuclear, Dreieich. pA3'pA and pA3'pA-2',3'-isopropylidene were synthesized by use of the triester-phosphite method [23]; the preparation of pA2'pA was performed by condensation of adenosine 5'-phosphorimidazolidine in aqueous solution by using lead nitrate as a catalyst as in [24]. The syntheses of the compounds employed will be described in detail elsewhere [25]. The preparation of Gp₃[¹⁴C]A has been published [26]. All the compounds used were characterized by ³¹P NMR spectroscopy (Bruker WP 250 F8). The ³¹P NMR (D₂O, pH 7) signals centered at: δ = +1.2 (3'-5' P), -0.1 (2'-5' P), -11 (α , γ -P), -22 (β -P) ppm (external standard: 85% H₃PO₄). Product analysis after enzymatic degradation was done by convenient chromatographic techniques including high-pressure liquid chromatography as in [27].

Isolation of liver nuclei from male rats (Wistar rats Bor: WISW, SPF TNO, 150–200 g) was performed as in [28] and [18]. DNA was determined as in [29]. Protein was measured according to the Biuret method.

The degradation studies of the ³H-labeled compounds Gp₃A3'pA, Gp₃A3'pA-isoprop, Gp₃A2'pA and Gp₃[¹⁴C]A were carried out using the following assay conditions: a 50- μ l suspension of rat liver nuclei (4 mg protein·ml⁻¹; 0.7 mg DNA·ml⁻¹) in buffer (0.44 M sucrose, 0.01 M K₂HPO₄, 0.003 M MgCl₂, 0.005 M NaN₃) was added to 100 μ l 0.05 M triethanolamine-HCl buffer (pH 7.2) containing 32 nmol of the employed compound in a total volume of at least 150 μ l at 25°C. All the degradation experiments were performed at saturating conditions over a period of 20 min (fig.2). Twenty- μ l-aliquots of the incubation mixture taken during assaying were denatured with 5 μ l perchloric acid (15%) and neutralized after centrifugation. The determination of the ³H- or ¹⁴C-labeled reaction products was performed by thin-layer chromatography (TLC) on PEI-cellulose plates (Macherey and Nagel, Düren) using 0.8 M KNO₃ (pH 5.7) as the mobile phase. The radioac-

tive spots of the catabolites [^3H]GMP ($R_f = 0.25$) and [^3H]guanosine ($R_f = 0.65$) or [^{14}C]AMP ($R_f = 0.37$) and [^{14}C]adenosine ($R_f = 0.67$), respectively, as well as the non-degraded capped compounds ($R_f = 0.18$) were detected by a TLC-Linear Analyzer LB 2821 (Berthold, Wildbad).

3. RESULTS AND DISCUSSION

The cleavage of the unmethylated cap moiety Gp_3A in the compounds [^3H]Gp₃A3'pA, [^3H]Gp₃A3'pA-isoprop and [^3H]Gp₃A2'pA was investigated in rat liver nuclei in comparison to $\text{Gp}_3[^{14}\text{C}]\text{A}$ as the standard substrate. From previous studies it is known that cap-type structured dinucleoside triphosphates as Gp_3A , $\text{m}^7\text{Gp}_3\text{A}$ and other guanosine-modified analogs were hydrolyzed by a dinucleoside triphosphatase (EC 3.6.1.x) in rat liver nuclei [18]. Similar nucleoside triphosphatase activities have been found in extracts of HeLa cells [7], tobacco [19], potato [16] and more recently in human placenta [17]. The human enzymes [7,17] recognize and hydrolyze $\text{m}^7\text{Gp}_3\text{N}$ structures (N is any base); i.e., these enzymes are specific with respect to N7-methylation of the 5'-terminal guanosine and do not hydrolyze unmethylated Gp_3N compounds. Unlike mammalian cytoplasmic cap-splitting activities, the vegetable enzymes [16,19] and the nuclear triphosphatase [18] hydrolyze unmethylated Gp_3N structures as well. From the partially enriched HeLa cell activity as well as the 1400-fold purified human placental enzyme it is well known, that both failed to cleave the cap moiety when extended in the 3'-direction by the addition of 3 [17] or more than 8 [7] nucleotides, respectively.

As the nucleotide chain length adjacent to the cap was shown to be important for the cap-degrading activity we have extended Gp_3A by adding nucleotides in the 3'- as well as the 2'-direction. The extension in both directions was performed to clarify whether or not a RNA-type 3'-5'-phosphodiester linkage is prerequisite for the decapping activity. Moreover, we have protected the 3'-terminus by a 2',3'-isopropylidene group ($\text{Gp}_3\text{A3'pA}$ -isoprop) to exclude Gp_3A -liberation by 3'-exoribonucleolytic degradation.

The results obtained are given in fig.2 and table 1. The hydrolysis rate of the Gp_3A moiety in




Fig.2. Enzymatic decapping of cap structured compounds in nuclei. [^3H]Gp₃A2'pA (●—●) not corrected for [^3H]GMP release due to [^3H]Gp₃A liberation from [^3H]Gp₃A2'pA; [^3H]Gp₃A3'pA (■—■); [^3H]Gp₃A3'pA-isoprop (○—○); $\text{Gp}_3[^{14}\text{C}]\text{A}$ (□—□). Data are given from one typical experiment. For details in assaying see section 2.

Table 1
Nuclear dinucleoside triphosphatase activity

Compound	Release of labeled	Degradation rate (nmol·min ⁻¹ ·mg nuclear protein ⁻¹) ^a
$\text{Gp}_3[^{14}\text{C}]\text{A}$	AMP,ADP	17.3 (± 2.0) ^b
[^3H]Gp ₃ A3'pA	GMP	8.4 (± 0.4)
[^3H]Gp ₃ A3'pA-ip	GMP	9.2 (± 2.6)
[^3H]Gp ₃ A2'pA	GMP	0.7 (± 0.5) ^c

^a The degradation rates were determined during the linear phase of assaying (up to 5 min) and are mean values of at least 3 independent experiments

^b Standard deviations are given in parentheses

^c Corrected for [^3H]GMP release due to [^3H]Gp₃A liberation from [^3H]Gp₃A2'pA by a (2'-5')-phosphodiesterase activity

[^3H]Gp₃A3'pA as well as [^3H]Gp₃A3'pA-isoprop decreases to about 50% when compared to Gp₃[^{14}C]A. The identical rate in releasing [^3H]GMP from both components shows that the nuclear triphosphatase is able to cleave the Gp₃A moiety in Gp₃A3'pA and Gp₃A3'pA-isoprop without previous liberation of Gp₃A. The rate reduction measured in the capped adenylates compared to Gp₃A may be based on the following fact: Gp₃A is in a way a symmetric dinucleotide with regard to the central β -phosphorous. The enzymatic attack, therefore, should be possible from both sides of the molecule. This assumption is in line with the release of ^{14}C -labeled ADP and AMP as degradation products. In this view, Gp₃A3'pA as well as Gp₃A3'pA-isoprop are asymmetric compounds which interact with the dinucleoside triphosphatase in an obviously side directed manner. Due to statistical means, therefore, the rate of cleavage of the Gp₃A moiety decreases about one half in both capped (3'-5')-adenylates compared to Gp₃A.

In contrast to capped (3'-5')-adenylates an extension of Gp₃A in the 2'-direction as realized in [^3H]Gp₃A2'pA prevents the nuclear dinucleoside triphosphatase to hydrolyze the Gp₃A moiety (fig.2, table 1). The small [^3H]GMP release measured (fig.2) is mainly due to [^3H]Gp₃A liberation from [^3H]Gp₃A2'pA during the course of incubation by a (2'-5')-phosphodiesterase activity obviously present in nuclei [30]; i.e., Gp₃A2'pA is not or, if any, a very poor substrate of the nuclear triphosphatase. The different behaviour of capped (3'-5')- and (2'-5')-adenylates shows that both the cap- as well as the (3'-5')-nucleotide moieties interact specifically with the nuclear enzyme. Only a RNA-type 3'-5'-linked nucleotide adjacent to the cap contacts the nuclear triphosphatase in the adequate way necessary to trigger cap degradation (fig.3). Thus our results stress the assumption in [17] that the placental m⁷Gp₃N-phosphatase appears to attack the cap from the penultimate base side of the molecule due to the fact that the addition of 3 or more nucleotides adjacent to the cap prevents the interaction with the enzyme.

The data presented support the idea that rat liver nuclear dinucleoside triphosphatase acts *in vivo* as a decapping enzyme. This nuclear triphosphatase seems to be involved in the nuclear degradation cascade of hnRNA. The rates of post-




Fig.3. Schematic representation of enzymatic attack on capped (3'-5')- and (2'-5')-adenylates.

transcriptional RNA maturation or degradation depend on the physiological state of the cell; i.e., the half-life of RNA species differs as, for example, shown for resting and stimulated lymphocytes [31]. The degradative function of the nuclear triphosphatase is further substantiated by the ability of this enzyme to attack unmethylated caps which represent early species during RNA processing [21,31-33]. These results confirm the findings in [34] showing the importance of the nucleus for RNA degradation. In conclusion, the nuclear dinucleoside triphosphatase is involved *in vivo* in the nuclear degradation cascade of hnRNA and thereby recycles excess capped RNA precursors.

ACKNOWLEDGEMENTS

We are grateful to Drs K.-S. Boos and S. Bornemann, Paderborn as well as Professor K.P. Schäfer, Bochum for fruitful discussions, and to the government of Nordrhein-Westfalen and the Fonds des Verbandes der Chemischen Industrie for financial support.

REFERENCES

- [1] Rottman, F., Shatkin, A.J. and Perry, R.P. (1974) Cell 3, 197.
- [2] Reddy, R., Ro-Choi, T.S., Henning, D. and Busch, H. (1974) J. Biol. Chem. 249, 6486.

- [3] Adams, J.M. and Cory, S. (1975) *Nature* 255, 29.
- [4] Shatkin, A.J. (1976) *Cell* 9, 645.
- [5] Furuichi, Y., La Finandra, A. and Shatkin, A.J. (1977) *Nature* 266, 235.
- [6] Shimotohno, K., Kodama, Y., Hashimoto, J. and Miura, K. (1977) *Proc. Natl. Acad. Sci. USA* 74, 2734.
- [7] Nuss, D.L. and Furuichi, Y. (1977) *J. Biol. Chem.* 252, 2815.
- [8] Wodnar-Filipowicz, A., Szezesna, E., Zan-Kowalozewska, M., Muthukrishnan, S., Szybiak, H., Lagooki, A.B. and Filipowicz, W. (1979) *Eur. J. Biochem.* 22, 60.
- [9] Lavers, G.C. (1977) *Mol. Biol. Rep.* 3, 413.
- [10] Stevens, A. (1980) *J. Biol. Chem.* 255, 3080.
- [11] Banerjee, A.K. (1980) *Microbiol. Rev.* 44, 175.
- [12] Shinshi, H., Miwa, M., Sugimura, T., Shimotohno, K. and Miura, K. (1976) *FEBS Lett.* 65, 254.
- [13] Kole, R., Sierakowska, H. and Shugar, D. (1976) *Biochim. Biophys. Acta* 438, 540.
- [14] Nuss, D.L., Furuichi, Y., Koch, G. and Shatkin, A.J. (1975) *Cell* 6, 21.
- [15] Yamaguchi, K., Miura, Y. and Miura, K. (1982) *FEBS Lett.* 139, 197.
- [16] Zan-Kowalczevska, M., Bretner, M., Sierakowska, H., Szczesna, E., Filipowicz, W. and Shatkin, A.J. (1977) *Nucleic Acids Res.* 4, 3065.
- [17] Nuss, D.L., Altschuler, R.E. and Peterson, A.J. (1982) *J. Biol. Chem.* 257, 6224.
- [18] Bornemann, S. and Schlimme, E. (1982) *Z. Naturforsch.* 37c, 818.
- [19] Shinski, H., Miwa, M., Kato, K., Noguchi, M., Matsushima, T. and Sugimura, T. (1976) *Biochemistry* 15, 2185.
- [20] Hagenbüchle, O. and Schibler, U. (1981) *Proc. Natl. Acad. Sci. USA* 78, 2283.
- [21] Grunert, B. and Schäfer, K.P. (1982) *Exp. Cell Res.* 140, 137.
- [22] Michels, W. and Schlimme, E. (1983) *Hoppe-Seyler's Z. Physiol. Chem.* 364, 1180.
- [23] Finnan, S.L., Varshney, A. and Letsinger, R.L. (1980) *Nucleic Acids Res., Symp. Ser. no.7*, 133.
- [24] Sleeper, H.L., Lohrmann, R. and Orgel, L.E. (1979) *J. Mol. Evol.* 13, 203.
- [25] Michels, W. and Schlimme, E. (1984) submitted.
- [26] Bornemann, S. and Schlimme, E. (1981) *Z. Naturforsch.* 36c, 135.
- [27] Hagemeyer, E., Bornemann, S., Boos, K.-S. and Schlimme, E. (1982) *J. Chromatogr.* 237, 174.
- [28] Jungblut, P.W., Kallweit, E., Sierralta, W., Truitt, A.J. and Wagner, R.K. (1978) *Hoppe-Seyler's Z. Physiol. Chem.* 359, 1259.
- [29] Burton, K. (1956) *Biochem. J.* 62, 315.
- [30] Michels, W. and Schlimme, E. (1983) *Z. Naturforsch.* 38c, 631.
- [31] Kecskemethy, N. and Schäfer, K.P. (1982) *Eur. J. Biochem.* 126, 573.
- [32] Knowler, J.T. (1982) *Biochem. Educ.* 10, 130.
- [33] Mizumoto, K. and Lipmann, F. (1979) *Proc. Natl. Acad. Sci. USA* 76, 4961.
- [34] Harris, H. (1963) *Nature* 198, 184.